.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,113,942

« Back to Dashboard

Claims for Patent: 6,113,942

Title: Pharmaceutical composition for piperidinoalkanol compounds
Abstract:The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient.
Inventor(s): Ortyl; Thomas T. (Overland Park, KS), Skultety; Paul F. (Leawood, KS), Mitchell; Kristen C. (Lee's Summit, MO), Phadke; Deepak S. (Olathe, KS), Attarchi; Faraneh (Kansas City, MO), Pierce; Marguerite L. (Fairway, KS), Schoeneman; Aaron W. (Lee's Summit, MO), Schnitz; Joseph M. (Kansas City, MO)
Assignee: Aventis Pharmaceuticals Inc. (Bridgewater, NJ)
Application Number:09/157,841
Patent Claims: 1. A pharmaceutical composition in solid unit dosage form comprising:

a) a therapeutically effective amount of a piperidinoalkanol compound of the formula ##STR10## wherein X is a number ranging from about zero to 5, and the individual optical isomers thereof; and

b) inert ingredients comprising croscarmellose sodium, lactose, microcrystalline cellulose, pregelatinized starch and gelatin.

2. A pharmaceutical composition in solid dosage form comprising:

a) a therapeutically effective amount of a piperidinoalkanol compound of the formula ##STR11## wherein X is a number ranging from about zero to 5, and the individual optical isomers thereof; and

b) inert ingredients comprising croscarmellose sodium, microcrystalline cellulose, lactose, pregelatinized starch, gelatin and magnesium stearate.

3. A pharmaceutical composition in solid unit dosage form comprising:

a) a therapeutically effective amount of a piperidinoalkanol compound of the formula ##STR12## wherein X is a number ranging from about zero to 5, and the individual optical isomers thereof; and

b) inert ingredients comprising croscarmellose sodium, microcrystalline cellulose, pregelatinized starch, and magnesium stearate.

4. The pharmaceutical composition in solid unit dosage form according to either of claims 1, 2, or 3 wherein the piperidinoalkanol compound is present in an amount of about 5 mg to about 180 mg.

5. The pharmaceutical composition in solid unit dosage form according to either of claims 1, 2, or 3 wherein the 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-.alpha.,.al pha.-dimethylbenzeneacetic acid hydrochloride has a particle surface area of greater than about 1.0 m.sup.2 /g.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc